Clinical Trials
4 trialsNCT06295809 2026-05-08
INTerpath-007
Merck Sharp & Dohme LLC
Phase 2/3 Terminated
NCT06947928 2026-04-17
Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma
TuHURA Biosciences, Inc.
Phase 2/3 Recruiting
NCT05786716 2025-12-02
DETERMINE
Cancer Research UK
Phase 2/3 Recruiting
NCT00367042 2015-04-16
Study to Determine if Tissue Scored With a Scalpel Results in Any Noticeable Marks
University of California, Davis
Phase 2/3 Completed